| Prev Close | 1.34 |
| Open | 1.34 |
| Day Low/High | 1.30 / 1.35 |
| 52 Wk Low/High | 0.70 / 2.05 |
| Volume | 49.99K |
| Avg Volume | 131.50K |
| Exchange | NASDAQ |
| Shares Outstanding | 16.24M |
| Market Cap | 22.72M |
| EPS | -0.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
These stocks trading for less than $10 a share are within range of breaking out and trading higher from current levels.
Clinically validated BREVAGenplus(R) more accurately identifies sporadic breast cancer risk
Personalized, Genetically-Based Test Enables Physicians to Tailor Breast Cancer Screening and Reduction Services Based on Individual Risk
These stocks look poised to break out and trade higher from current levels.
Shares of Genetic Technologies Ltd. (GENE) rose Monday after the molecular diagnostics company announced that two new breast health centers will start to offer BREVAGenplus®.
Can we wait for it to tell us whether to buy or avoid it.?
Findings presented at the 2014 San Antonio Breast Cancer Symposium
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
